Tenapanor Scores FDA Advisory Committee Endorsement
An FDA advisory committee said the benefits of tenapanor for treating hyperphosphatemia in patients on dialysis outweighed its risks as both mono- and combo-therapy.
United States Vanderbilt University Juliab Lewis Susanr Mendley National Institute Of Diabetes Vanderbilt University Medical Center
Source: medscape.com